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Alzheimer's disease (AD) is the most common form of 
late-onset dementia. Key pathological features of AD con-
sist of the deposition of amyloid-β peptide (Aβ) and hy-
perphosphorylated tau aggregates that, together, are linked 
with synapse loss and neuronal cell death, as well as acti-
vation of microglia and astrocytes (Holtzman et al., 2011). 
Rare forms of autosomal dominant inherited AD are caused 
by mutations in genes involved in the Aβ processing path-
way, such as amyloid precursor protein (APP) and preseni-
lin 1 (PSEN1; Tanzi, 2012). The origin of nonfamilial AD 
is less well understood and may depend on a combination 
of genetic and nongenetic risk factors (Tanzi, 2012). Re-
cent genome-wide association studies have identified rare 
variants of genes that encode immune receptors as risk fac-
tors (Guerreiro and Hardy, 2014; Karch and Goate, 2015). 
Among these, the arginine 47 histidine (R47H) variant of 
triggering receptor expressed on myeloid cells 2 (TREM2) 
has been found in several cohorts of patients. TREM2 is a 
cell surface receptor of the Ig superfamily that is expressed 
in microglia of the central nervous system and in other 
tissue macrophages, and binds phospholipids and other 
polyanionic ligands (Paloneva et al., 2002; Daws et al., 2003; 
Cannon et al., 2012; Wang et al., 2015). TREM2 transmits 
intracellular signals through the associated adaptor DNAX 
activation protein of 12 kD (DAP12), which recruits the 
protein tyrosine kinase spleen tyrosine kinase. TREM2 
signaling promotes survival, proliferation, phagocytosis, 
and secretion of cytokines and chemokines (Takahashi et 
al., 2005; Otero et al., 2009; Wang et al., 2015). TREM2- 
induced signals also augment activation of integrins, thereby 
facilitating adhesion and remodeling of the actin cytoskele-
ton (Takahashi et al., 2005).
We and others have recently examined the impact of 
TREM2 deficiency on the microglial response to Aβ depo-
sition in mouse models of AD, including APP PS1-21 and 
5XFAD mice (Ulrich et al., 2014; Jay et al., 2015; Wang et 
al., 2015). All studies showed that TREM2 deficiency af-
fects clustering of microglia around the plaques. However, 
whether Aβ-reactive microgliosis involves resident microg-
lia (Wang et al., 2015) or myeloid cells derived from pe-
ripheral blood monocytes (Jay et al., 2015) is still up for 
debate. Additionally, the analysis of Aβ accumulation in 
different mouse models of AD yielded inconsistent results 
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(Tanzi, 2015). In 8-mo-old 5XFAD mice, TREM2 defi-
ciency resulted in increased hippocampal Aβ accumulation, 
consistent with a protective function of TREM2 (Wang et 
al., 2015). In 4-mo-old APP PS1-21 mice lacking TREM2, 
however, hippocampal Aβ accumulation was paradoxically 
reduced despite the myeloid cell defect, a finding that was 
interpreted to indicate that TREM2 deficiency protects 
against AD pathogenesis (Jay et al., 2015).
In this study, we determined whether the Aβ-reactive 
myeloid cells are derived from resident microglia or from 
infiltrating monocytes in parabiosis experiments. Using 
this approach, we observed no infiltration of monocytes 
around Aβ plaques in either 5XFAD or APP PS1-21 mice. 
Moreover, staining of brain sections for the proliferation 
marker Ki67 revealed that TREM2 is necessary for local 
proliferation of microglia around the plaques. To explain 
the conflicting results regarding the impact of TREM2 
deficiency on Aβ accumulation, we hypothesized that 
whereas TREM2 deficiency results in early impairment 
of the microglial response to Aβ deposits in all AD mod-
els, changes in Aβ burden develop more slowly; therefore, 
the discrepancies in Aβ accumulation may be a result of 
the varied timing of the analyses—8 mo in 5XFAD mice 
(Wang et al., 2015) and 3–4 mo in APP PS1-21 mice (Ul-
rich et al., 2014; Jay et al., 2015). To test this, we exam-
ined microgliosis and Aβ deposition at early time points (4 
mo) in TREM2-deficient and -sufficient 5XFAD mice. We 
found that Aβ deposition was quantitatively similar in the 
presence and absence of TREM2. However, TREM2 did 
affect microglial clustering and the structure of Aβ plaques 
at this early time point; in 5XFAD mice lacking TREM2, 
Aβ plaques appeared more diffuse, had altered Aβ sub-
species composition, and were associated with increased 
neuritic dystrophy compared with those in TREM2-suffi-
cient 5XFAD mice. Collectively, our data demonstrate that 
TREM2 is required for the early expansion of microglia 
around Aβ plaques that limits plaque diffusion as well as 
amyloid-related neuronal damage.
RES ULTS AND DIS CUS SION
Aβ-reactive myeloid cells derive from 
brain-resident microglia
It has been proposed that the TREM2-dependent microg-
lial response to Aβ plaques in APP PS1-21 mice relies on 
the recruitment of blood monocytes (Jay et al., 2015). We 
first determined whether blood monocytes in 5XFAD 
mice express TREM2 and hence might respond to puta-
tive TREM2 ligands present in peripheral blood during 
Aβ accumulation. Staining of monocytes from 5XFAD 
and wild-type mice with anti-TREM2 revealed no de-
tectable expression of TREM2 (Fig.  1  A). However, it 
remained possible that monocytes up-regulate TREM2 
upon infiltrating the brain and, therefore, TREM2 would 
be required for clustering of infiltrating monocyte around 
Aβ plaques. To definitively test for contribution of blood 
monocytes to the microglial pool in 5XFAD mice, we 
performed parabiosis experiments in which the blood 
circulation of CD45.2+ 5XFAD mice was joined with 
that of age-matched congenic CD45.1+ B6 mice (Fig. 1, 
B–E). Parabiosis was performed in 4-mo-old mice or in 
8-mo-old mice. After 4 weeks, tissues were analyzed. Total 
blood leukocytes and lung alveolar macrophages showed a 
marked degree of exchange (Fig. 1, B and C). In contrast, 
nearly all microglia in 5XFAD and B6 mice maintained 
expression of the original CD45.2 or CD45.1 marker, re-
spectively, consistent with minimal monocyte infiltration 
(Fig. 1, B–E). Upon expanding this analysis to APP PS1-21 
mice we found results consistent with a lack of infiltration 
of CD45.1+ cells into the brain of CD45.2+ APP PS1-21 
mice (Fig. 1, F and G). Thus, the contribution of periph-
eral monocytes to the microglial pool in both 5XFAD and 
APP PS1-21 models of AD is negligible.
TREM2 deficiency affects plaque-associated 
microglial proliferation
We previously observed an impaired microglial response to 
Aβ in 8-mo-old Trem2−/− 5XFAD mice (Wang et al., 2015). 
Defective microglial clustering around plaques was also de-
tected at earlier time points in 3- or 4-mo-old Trem2−/− 
APP PS1-21 mice (Ulrich et al., 2014; Jay et al., 2015). To test 
whether Trem2−/− 5XFAD mice also had an early microglial 
defect, we compared the total number of microglia in 4- and 
8-mo-old 5XFAD and Trem2−/− 5XFAD mice. Microglial 
numbers were similar in 4-mo-old 5XFAD and Trem2−/− 
5XFAD mice. In contrast, at 8 mo of age, 5XFAD mice 
had a clear increase in total microglia, whereas age-matched 
Trem2−/− 5XFAD had fewer microglia (Fig. 2 A). We next 
assessed the number of plaque-associated microglia in 4-mo-
old 5XFAD, Trem2+/− 5XFAD, and Trem2−/− 5XFAD mice. 
5XFAD mice had significantly more microglial clustering 
around plaques than did Trem2+/− and Trem2−/− 5XFAD 
mice (Fig. 2, B and C). Thus, an impairment of microglial 
response to Aβ deposits was detectable even at 4 mo of age 
in Trem2−/− 5XFAD mice.
Given that brain-resident microglia are capable of 
self-renewal and expansion (Gomez Perdiguero et al., 2013; 
Greter and Merad, 2013; Prinz and Priller, 2014), we next 
sought to determine if microglia associated with plaques 
resulted from the proliferation of resident microglia. We 
analyzed nuclear localization of Ki-67, a well-characterized 
proliferation marker, in microglia from 4-mo-old 5XFAD 
and Trem2−/− 5XFAD mice in relation to their proximity 
to a plaque (Fig.  2, D–G). In 5XFAD mice, the major-
ity of Ki-67+ microglia detected were in close proximity 
to Aβ plaques (mean distance = 21.1 µm; Fig.  2, D and 
E). In contrast, plaque-associated Ki-67+ microglia were 
nearly undetectable in Trem2−/− 5XFAD mice (Fig. 2 F). 
Additionally, we observed that Ki-67+ microglia in 5XFAD 
mice were preferentially located near plaques with a greater 
volume (Fig.  2 G). As more proliferating microglia were 
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observed near larger plaques in 5XFAD mice, we sought 
to determine if there was a correlation between the size of 
a plaque and the number of microglia associated with it. 
We found that, in 5XFAD mice, the number of microglia 
associated with a given plaque was positively correlated 
to the size of the plaque (Fig. 2 H). This correlation was 
not as strong in Trem2+/− 5XFAD and not apparent in 
Trem2−/− 5XFAD (Fig. 2 H).
Finally, as microglia are phagocytic and have been 
demonstrated to engulf pieces of plaques, we wished to 
examine the number of microglia which had internal-
ized portions of plaques in 5XFAD and Trem2−/− 5XFAD 
Figure 1. Lack of monocyte contribu-
tion to amyloid-associated microglia. 
(A) Surface expression of TREM2 among Ly6C+ 
CD11b+CD115+ blood monocytes in WT and 
5XFAD mice. Trem2−/− mice were used as 
negative controls. (B–E) Parabiosis was per-
formed by joining blood circulation of 4- or 
8-mo-old 5XFAD with age matched B6.CD45.1 
congenic mice for 4 wk. (B) CD45+ blood leu-
kocytes, CD11c+SiglecF+ lung alveolar mac-
rophages, and brain CD11b+F4/80+ microglia 
from parabionts were analyzed by flow cytom-
etry. (C) Frequencies of CD45.1+ and CD45.2+ 
cells were compared in parabiotic partners. 
(D and E) Representative images of brain sec-
tions of an 8-mo-old 5XFAD parabiont stained 
with X-34 (red) for Aβ plaques and Iba-1 
(white) for microglia. Contribution of host- 
and donor-derived microglia was examined 
using antibodies specific for CD45.2 (green; 
D) and CD45.1 (green; E). Nuclei were visual-
ized with To-pro3 (blue). Bar, 100 µm (F and 
G) Parabiosis was performed using APP PS1-21 
mice and age-matched B6.CD45.1 congenic 
mice for 9 wk. Parabionts were analyzed as 
described above. Data represent a total of 
five to seven mice per group in A–E and four 
mice per group in F and G.
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mice by measuring uptake of methoxy-X04, which binds 
to fibrillar Aβ (Heneka et al., 2013). Microglia in Trem2−/− 
5XFAD mice incorporated less methoxy-X04 than mi-
croglia from 5XFAD mice (Fig. 2, I and J), corroborating 
that TREM2 deficiency impairs productive interactions 
between microglia and plaques. Collectively, these data 
indicate that TREM2-dependent accrual of resident mi-
croglia is a process that initiates early in Aβ deposition and 
depends at least in part on local proliferation of microglia 
around growing Aβ plaques.
Figure 2. Impaired microglial response to Aβ deposits in Trem2−/− 5XFAD mice is apparent by 4 mo. (A) Total numbers of microglia in the cortices 
and hippocampi of 5XFAD and Trem2−/− 5XFAD mice at 4 and 8 mo of age. (B and C) Microglial response to Aβ plaques in 4-mo-ol 5XFAD, Trem2+/− 5XFAD, 
and Trem2−/−5XFAD mice. (B) Representative images show matching cortical regions stained with X-34 (red) for amyloid plaques and Iba-1 (white) for mi-
croglia. Nuclei were visualized with To-pro3 (blue). (C) Numbers of microglia within 15 or 30 µm of Aβ plaques. (D–F) Microglia proliferation in 5XFAD and 
Trem2−/− 5XFAD mice was assessed by determining nuclear localization of Ki-67. (D) Representative sectional view of a confocal image shows expression of 
Ki-67 (green), microglia (Iba-1; white), and nuclei (blue). The proximity of Ki-67+ microglia to Aβ plaques (X-34, red), in cortices of 5XFAD mice is visualized. 
(E) Proximity of Ki-67+ microglia to the nearest plaque in cortices of 5XFAD. Unfilled circles (*) represent outliers as determined by q-test. (F) Frequencies of 
Ki-67+ microglia per HPF in 5XFAD and Trem2−/−5XFAD mice. (G) The volume of all observed Aβ plaques and Aβ plaques with Ki-67+ in close proximity were 
compared. (H) The log10-transformed volume of plaques was plotted against the number of microglia within 15 µm. Numbers represent slope ±95% confi-
dence interval. (I and J) 5XFAD and Trem2−/− 5XFAD mice were injected with methoxy-X04 and the percentage of microglia with internalized methoxy-X04 
(indicative of fibrillar Aβ) was determined by flow cytometry. (I) Representative plots show methoxy-x04 positivity of CD11b+CD45lo cells. APP transgene 
negative (APP–) littermates were used as negative controls. (J) The frequency of methoxy-X04+ microglia was quantified. Bars: (B) 100 µm; (D) 20 µm. Error 
bar represents mean ± SEM. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001, Mann-Whitney (A, F, and J) and q-test (E). Data represent a total of five to seven mice 
per group (A–F). For confocal images, a total of four random HPF were analyzed per mouse.
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TREM2 deficiency alters the physical appearance and 
composition of Aβ plaques
To determine if TREM2 impacted Aβ deposition at 4 mo 
of age, we compared the total insoluble Aβ1-42 and Aβ1-40 
from 5XFAD, Trem2+/− 5XFAD, and Trem2−/− 5XFAD 
mice in the hippocampus and cortex by ELI SA. We 
found no differences in the total Aβ1-42 or Aβ1-40 present 
in any of the genotypes (Fig.  3, A–D). Consistent with 
these findings, we did not detect a significant difference in 
X-34 staining in the cortices of Trem2−/− 5XFAD mice 
(Fig.  3  E). However, TREM2 had a remarkable influ-
ence on the structure of Aβ plaques. Fibrillar Aβ plaques 
from 5XFAD mice at 4 mo of age were compact with 
well-defined, condensed cores and few surrounding diffuse 
structures (Fig.  3  F). In contrast, plaques from Trem2−/− 
5XFAD mice appeared more loosely packed with smaller 
cores and many fiber-like structures extending outwards 
(Fig. 3 F). A quantitative morphology index based on the 
perimeter versus area of Aβ plaques in multiple brain sec-
tions confirmed TREM2-dependent differences in the 
morphology of Aβ plaques (Fig. 3 G). Furthermore, com-
putation of pixels within Aβ plaque images demonstrated 
that plaque density was also TREM2 dependent (Fig. 3, H 
and I). Shape and density differences were also apparent in 
8-mo-old mice (Fig. 3, F–I).
We sought to determine whether plaques from 5XFAD 
and Trem2−/− 5XFAD mice also differed in the biochemical 
profile of the Aβ deposits. It has been previously observed 
that Aβ plaques contain several Aβ subspecies resulting from 
truncation and/or posttranslational modification of the Aβ1-42 
peptides (DeMattos et al., 2012; Kummer and Heneka, 2014), 
including Aβp3-42, a truncated form of Aβ with a pyrogluta-
mate modification at position 3 (Harigaya et al., 2000). To 
determine if the accumulation of Aβ subspecies was affected 
by TREM2 deficiency, we analyzed the insoluble fractions of 
Aβ from the brains of 8-mo-old 5XFAD, Trem2+/− 5XFAD, 
and Trem2−/− 5XFAD mice by denaturing acid/urea PAGE, 
followed by immunoblotting using antibodies against various 
epitopes of Aβ (DeMattos et al., 2002). We observed that the 
abundance of Aβp3-42 relative to Aβ1-42 was reduced in the hip-
pocampi of Trem2+/− 5XFAD and Trem2−/− 5XFAD mice. 
In addition, the relative abundance of other Aβ subspecies, 
such as Aβ1-42-1 and Aβ1-42-2, was reduced in a similar fash-
ion in Trem2+/− 5XFAD and Trem2−/− 5XFAD mice (Fig. 3, 
J and K). Thus, TREM2 deficiency not only influences the 
physical appearance of the plaques, but also alters the Aβ 
subspecies composition.
TREM2 expression is important in limiting neuronal toxicity 
during the early stages of Aβ deposition
Because large, swollen, dystrophic axons and dendrites 
(neurites) are associated with Aβ plaques in AD and in 
mouse models with Aβ deposition (Masliah et al., 1996; 
Brendza et al., 2003), we examined whether altered plaque 
morphology and composition was also associated with in-
creased neuronal damage. We stained sections for the N 
terminus (NT) of APP (NT-APP), which accumulates in 
dystrophic neurites, and measured NT-APP+ neuronal 
processes within 30 µm of Aβ plaques. We found that the 
number of dystrophic neurites was significantly increased 
in Trem2−/− 5XFAD mice compared with 5XFAD mice 
(Fig.  4, A–C). We also stained sections for hyperphos-
phorylated tau and found an increase in the number and 
volume of hyperphosphorylated tau punctae in Trem2−/− 
5XFAD mice compared with 5XFAD mice (Fig. 4, D–E). 
Thus, the altered Aβ plaque shape and density associated 
with TREM2 deficiency observed in Fig. 3 were associ-
ated with increased toxicity to neural processes. Overall, 
these data indicate that TREM2-mediated microglial re-
sponse is crucial in compacting Aβ plaques and preventing 
damage to the adjacent axons and dendrites.
Concluding remarks
A previous study proposed that TREM2 is important for in-
filtration of blood-derived monocytes into the brain, which 
then mediate Aβ plaque-associated reactive microgliosis (Jay 
et al., 2015). This study was based on phenotypic charac-
terization of microgliosis with monocytic- and microglia- 
specific markers, along with bone marrow grafts, which en-
able tracking of congenically marked peripheral monocytes 
that traffic into the brain. However, phenotypic markers of 
migroglia, such as low expression of CD45 and high expres-
sion of the P2Y(12) receptor, are altered upon microglial 
activation and therefore do not precisely discriminate mi-
croglia from monocytes (Butovsky et al., 2014). Moreover, 
whole-body irradiation before bone marrow grafts causes 
a blood–brain barrier (BBB) leakage, facilitating an influx 
of blood monocytes that may obscure the relative contribu-
tion of distinct myeloid cell types during Aβ accumulation 
(Mildner et al., 2011). As parabiosis models do not rely on 
methods that may compromise the BBB, they may be more 
reliable than bone marrow grafts for determining the origin 
of microglia. Our parabiosis experiments indicate that the 
contribution of peripheral blood monocytes to microgliosis 
in mouse models of Aβ accumulation with an unperturbed 
BBB is undetectable. Moreover, staining of brain section 
with Ki67 suggested that Aβ-associated microgliosis depends 
at least in part on the proliferation of brain-resident microg-
lia. Consistent with the predominant impact of brain-resi-
dent microglia in the response to amyloid, two recent studies 
showed that in a transgenic mouse model of Aβ deposition 
in which microglia are depleted after intracranial injection 
of gangliocyclovir and replaced with infiltrating monocytes, 
the infiltrating cells co-localize with Aβ plaques only after a 
long period of time and are not efficient at clearing plaques 
(Prokop et al., 2015; Varvel et al., 2015).
Recently, microglia around Aβ plaques were shown to 
form a physical barrier that prevents outward plaque expan-
sion and leads to compact plaque microregions with low 
Aβ1-42 affinity (Condello et al., 2015). Areas not covered by 
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microglia are less compact and contain protofibrillar hotspots 
with high Aβ1-42 affinity, which are associated with more se-
vere axonal dystrophy. Our data show that in the absence of 
TREM2-mediated microgliosis, Aβ plaques are less dense, 
more diffuse, and have some alterations in their biochemical 
features, exemplified by the reduced abundance of various 
Aβ subspecies in 5XFAD mice. Whether microglia influence 
the conversion of Aβ1-42 into other Aβ species by enabling 
Aβ-modifying enzymes to act more efficiently on aggregated 
forms of Aβ remains an open question. More importantly, 
Figure 3. TREM2 deficiency alters physical 
appearance and biochemical composition 
of amyloid plaques. (A–D) Accumulation of 
insoluble Aβ1-42 (A and B) and Aβ1-40 (C and D) 
in the cortices and hippocampi of 4-mo-old 
5XFAD, Trem2+/−5XFAD, and Trem2−/−5XFAD 
mice was determined by ELI SA. (E) Deposi-
tion of fibrillar Aβ in the cortices determined 
by X-34 staining. Levels of X-34 signal in the 
hippocampi were below the threshold of de-
tection. (F–I) Morphology of fibrillar plaques 
in 4-mo-old 5XFAD and Trem2−/−5XFAD 
mice. X-34–reactive fibrillar plaques were 
visualized using high-resolution confocal 
microscopy (F) and converted to heat-map 
images based on pixel intensity (H). Physical 
appearance of X-34-reactive fibrillar plaques 
was further quantified based on morphology 
(G) and pixel intensity (I). Diffuse shape and 
reduced density were also apparent in 8-mo-
old Trem2−/−5XFAD mice (F and H). (J) Rep-
resentative urea immunoblots showing the 
detection of Aβ1-42, Aβ1-42+1, Aβ1-42-1, Aβ1-42-2, 
and Aβp3-42 from insoluble fractions of hip-
pocampi from 5XFAD mice. (K) Quantification 
of insoluble Aβ species by urea immunoblots 
in the cortices and hippocampi of 5XFAD, 
Trem2+/−5XFAD, and Trem2−/−5XFAD mice. 
Abundance of Aβ1-42+1, Aβ1-42-1, Aβ1-42-2, and 
Aβp3-42 relative to Aβ1-42 is shown. Amount of 
Aβ used for standard curves are indicated. Bar, 
10 µm. *, P < 0.05; ** P < 0.01; ****, P < 0.0001, 
Mann-Whitney (G and I), two-way ANO VA 
(E and K). Data represent a total of 8–14 mice 
per group in A–E, eight mice per group in F–I 
and five mice per group in K. For confocal im-
ages, a total of four random HPF were analyzed 
per mouse. Error bar represents mean ± SEM.
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the altered Aβ plaque morphology associated with TREM2 
deficiency led to enhanced toxicity potential, as indicated 
by the increase in neuritic dystrophy. These results indicate 
that TREM2 has a major impact on the early containment 
of plaque diffusion by microglia. This impact is apprecia-
ble even at 4 mo of age, although the total Aβ present in 
TREM2-sufficient and -deficient 5XFAD mice is similar. 
We postulate that lack of this function for a long period 
of time leads to the increase in hippocampal Aβ1-42 levels 
in 8-mo-old TREM2-deficient mice that we previously re-
ported (Wang et al., 2015). Collectively, our studies highlight 
the protective role of TREM2 expression in brain-resident 
microglia by influencing the structure, biochemical compo-
sition, and toxicity of Aβ deposits and provide novel insights 
into the mechanisms by which TREM2 acts in the early 
stages of AD development.
MAT ERI ALS AND MET HODS
Mice. Trem2−/− mice were previously described (Turn-
bull et al., 2006). 5XFAD mice (Oakley et al., 2006) were 
purchased from The Jackson Laboratory (MMR RC) and 
crossed to Trem2−/− mice to generate Trem2+/−5XFAD and 
Trem2−/−5XFAD mice (Wang et al., 2015). Parabiotic mice 
were joined by the surgery core in the Hope Center for Neu-
rological Disorders (Washington University, St. Louis, MO). In 
brief, the skin along the opposite flanks of parabiotic pairs was 
joined under general anesthesia and pairs were housed for the 
indicated postoperative time. All animal studies were approved 
by the Washington University Animal Studies Committee.
Preparation of brain samples. For histological analysis, mice 
were anesthetized with ketamine and perfused with ice-cold 
PBS. Right-brain hemispheres were fixed in 4% PFA over-
night and placed in 30% sucrose before freezing and cutting on 
a freezing sliding microtome. Serial 40-µm coronal sections of 
the brain were collected from the rostral anterior commissure 
to caudal hippocampus as landmarks. For biochemical anal-
ysis, cortices, and hippocampi of the left-brain hemispheres 
were dissected out and flash frozen in liquid nitrogen.
Confocal imaging and quantification. 40-µm floating sections 
were stained with Iba-1 (Wako Pure Chemical Industries), 
X-34, and Topro-3 for visualization of microglia, plaques, and 
nuclei, respectively. Confocal images were collected using a 
Nikon A1R+ confocal microscope. 4–5 z-stack images (447 
× 447 × 30 µm; 1.25 µm thickness) were acquired per animal 
in random cortical regions and hippocampal regions. Images 
were then processed with Imaris (Bitplane). Coordinates of 
microglia and the location and volume of Aβ plaques were 
identified using the Particle and Surface function, respectively, 
and imported into Matlab (Mathworks). Number of microg-
lia within a 15- and 30-µm radius were then determined 
using an automated script. Dystrophic neurites were identi-
fied using 22C11 antibody against the N terminus of APP 
(EMD Millipore) followed by Alexa Fluor 555–conjugated 
anti–mouse IgG. Proliferating cells were identified using an 
anti–Ki-67-biotin (SolA15; eBioscience), followed by Alexa 
Fluor 488–conjugated streptavidin (Molecular Probes). Hy-
perphosphorylated tau was detected with AT8 antibody 
(Thermo Fisher Scientific). For plaque morphology analysis, 
high-resolution images were collected at 60× magnification 
with 1.5× digital zoom. Maximum intensity projection of the 
z-stack for each plaque was subsequently used for morpho-
logical analysis. To trace the shape of plaques, we applied a 
combination of intensity thresholds and edge detection in 
Matlab. First, the mean intensity of the brightest 10 pixels in 
the image (max intensity) was used to normalize the range. 
Pixels with intensity >0.5 times this max intensity formed a 
bright mask, and pixels <0.1 times this max formed a back-
ground mask. Next, edges were detected using the Laplacian 
of Gaussian method and dilated to generate a closed object. 
This object was overlaid with the bright mask, with the back-
Figure 4. Neuritic dystrophy and the amounts of phospho-tau in 
proximity to plaques are markedly increased in the absence of TREM2. 
(A–C) Neuritic dystrophy in 5XFAD and Trem2−/−5XFAD mice was visualized 
using 22C11 mAb against the APP N terminus (APP-NT). (A) Representative 
images show APP-NT+ neurites (green), Aβ plaques (X-34; red), and nuclei 
(To-pro3; blue). (B and C) Quantification of total volume and numbers of 
APP-NT+ neurites within 30 µm of Aβ plaques. (D–F) Hyperphosphorylated 
tau in 5XFAD and Trem2−/−5XFAD mice. Sections were stained with anti–
phospho-tau antibody (AT8; green) and Aβ plaques (red; D). Total volume of 
AT8+ neurites (E) and the number of AT8+ spots per HPF (F) were quantified. 
Bar, 20 µm. *, P < 0.05; ****, P < 0.0001, by Mann-Whitney. Data represent 
a total of four to eight mice per group. For confocal images, a total of four 
random HPF were analyzed per mouse. Error bar represents mean ± SEM.
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ground mask used to eliminate edges that may appear in the 
background pixels. Finally, holes <50 pixels in the resulting 
plaque tracing were filled in, and the entire shape was 
smoothed out by image erosion with a diamond-shaped ele-
ment to obtain the final shape. In summary, pixels brighter 
than 0.5 times max were included, pixels dimmer than 0.1 
times max were excluded, and pixels between those values 
were determined by edge detection. The density index was 
defined as (no. perimeter pixels) × 4π/total no. of pixels; this 
increases with shape complexity, but is roughly size invariant. 
A perfect circle of any size would have a value near 1, and 
more complex shapes would have larger values.
The diffuseness of staining was also assessed using the 
z-projected plaque image. First, pixels <1% of max intensity 
were discarded as background pixels that were not part of the 
plaque. For this analysis, the shape tracing described above, 
which favors crisp edges, was not included so that more dif-
fusely stained parts of the image could still be included in 
quantification. The cumulative intensity curve for the plaque 
image, starting with the brightest pixels and adding on pro-
gressively dimmer pixels, was compared with that of a “per-
fectly dense” curve, where all signal intensity is accounted for 
by maximum-intensity pixels. The area between these curves, 
normalized to the total intensity and the number of pix-
els, represents the deviation from a uniformly dense plaque. 
To obtain an index of density ranging from 0 to infinity, 
this area was inverted, and the lower limit of the resulting 
index, 2, was subtracted.
Denaturing acid/urea polyacrylamide gel electrophoresis 
(PAGE) and ELI SA. A mouse anti–Aβ33-42 antibody (21F12) 
was used for capture and biotinylated mouse anti–Aβ1-5 anti-
body (3D6) or mouse anti–Aβp3-42 antibody (mE8) was used 
for detection of Aβ1-42 or Aβp3-42, respectively (DeMattos et 
al., 2012), followed by streptavidin HRP (SouthernBiotech). 
All ELI SAs were developed using Super Slow ELI SA TMB 
(Sigma-Aldrich) and absorbance read on a Bio-Tek Epoch 
plate reader at 650 nm. The standard curves for each assay 
used synthetic human Aβ1-42 or Aβp3-42 peptide (AnaSpec). 
Denaturing Acid/Urea PAGE was performed as previously 
described (DeMattos et al., 2002). Subsequent standard im-
munoblotting was used for Aβ identification.
In vivo phagocytosis assay for fibrillar Aβ. Mice were injected 
with methoxy-X04 (R&D Systems) at 10 mg/kg in a PBS/
DMSO mixture at 1:1 ratio. Brains were isolated 3 h after 
injection and made into single-cell suspension as previously 
described (Heneka et al., 2013). Frequencies of methoxy-X04+ 
microglia cells were determined by flow cytometry using a 
Canto II (BD) and analyzed using FlowJo (Tree Star).
Statistics. Data in figures are presented as mean ± SEM. 
All statistical analysis was performed using Prism (GraphPad 
Software). Statistical analysis to compare the mean values for 
multiple groups was performed using a one- or two-way 
ANO VA with correction for multiple comparisons. Com-
parison of two groups was performed using a two-tailed 
unpaired t test (Mann Whitney). Values were accepted as 
significant if P ≤ 0.05.
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